By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Maridebart cafraglutide (MariTide; formerly AMG 133) is an investigational compound. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research / company IR data, not as medical advice. SaiyanMed does not list a MariTide / maridebart cafraglutide product SKU. This molecule is an antibody–peptide conjugate (biologic architecture), not a simple research-peptide vial like typical SaiyanMed catalog peptides. Educational hub only — indefinitely unless Eric explicitly green-lights a biologic conjugate SKU (unlikely).
Quick answer
Maridebart cafraglutide — trade/development name MariTide; former code AMG 133 — is Amgen’s investigational long-acting peptide–antibody conjugate (also described by Amgen as a bispecific GLP-1 receptor agonist / GIP receptor antagonist molecule). Public sponsor language says it activates the GLP-1 receptor via peptide agonist arms while blocking the GIP receptor via an antibody component, and is studied as a once-monthly (or less frequent) subcutaneous investigational product [Amgen MARITIME story; Amgen Phase 2 press 2025-06-23; NEJM Phase 2 DOI 10.1056/NEJMoa2504214].
Phase 2 dose-ranging data (NCT05669599; n=592) were presented at ADA 2025 and published in NEJM (23 June 2025). The Phase 3 MARITIME chronic weight-management program includes pivotal MARITIME-1 (obesity/overweight without T2D; NCT06858839; n=3853 actual) and MARITIME-2 (obesity/overweight with T2D; NCT06858878; n=1105 actual). Both were ACTIVE_NOT_RECRUITING on ClinicalTrials.gov fetch 2026-11-05, with estimated primary completion 2027-01-21. No Phase 3 topline efficacy results are claimed in this hub [NCT06858839; NCT06858878].
MariTide is not the same molecule as:
| Peer (research context) | Public MoA headline | Why it is different |
|---|---|---|
| Retatrutide | Unimolecular GIP / GLP-1 / glucagon agonist triple | Agonizes GIPR; peptide (not Ab–peptide conjugate) |
| Tirzepatide / VK2735-class | Dual GIP / GLP-1 agonists | Dual agonism at GIPR — opposite public GIP polarity vs MariTide’s GIPR antagonism |
| Semaglutide | Mono GLP-1 agonist peptide | No antibody / GIPR-block architecture |
| Zenagamtide | Unimolecular GLP-1 + amylin | Amylin pathway; peptide |
| CagriSema | Two peptides (cagrilintide + semaglutide) | Fixed-dose / co-admin combo, not one Ab–peptide conjugate |
| Survodutide | Dual GCGR + GLP-1R peptide | Glucagon dual — different receptors and modality |
Antibody–peptide conjugate architecture
What Amgen publicly says the molecule is
Amgen’s June 2025 press “About MariTide” language describes MariTide as a bispecific glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, and as a pioneering peptide–antibody conjugate with a long half-life and dual mechanism of action [Amgen Phase 2 press 2025-06-23]. The company’s MARITIME program story similarly calls it an antibody-peptide conjugate that blocks the GIP receptor while activating the GLP-1 receptor, studied as a monthly or even less frequent injection [Amgen MARITIME story].
The NEJM Phase 2 abstract frames maridebart cafraglutide as a long-acting peptide–antibody conjugate that combines GLP-1 receptor agonism and GIP receptor antagonism [NEJM DOI 10.1056/NEJMoa2504214].
| Component (sponsor framing) | Public role |
|---|---|
| Antibody portion | GIPR antagonist (blocks GIP receptor signaling) |
| Peptide agonist arms | GLP-1R agonism |
| Combined modality | Peptide–antibody conjugate / Ab–peptide conjugate — not a free small peptide API alone |
Why this matters for RUO / catalog literacy
SaiyanMed’s typical research-peptide SKUs are synthetic peptides supplied as lyophilized powders with peptide-oriented COA packets (RP-HPLC, intact-mass LC-MS, peptide content). MariTide’s public design is a biologic conjugate: antibody + peptide arms. That implies:
- Different manufacturing / analytical identity problems (antibody integrity, conjugation stoichiometry, residual host-cell proteins, aggregation, anti-drug antibodies in clinical settings — not interchangeable with “peptide purity %”).
- Not a drop-in analogue of a 10 mg research vial of a mono-GLP-1 or dual-agonist peptide.
- This hub is educational identity only. There is no implied “buy MariTide research powder” path from SaiyanMed.
GIP receptor blockade + GLP-1 agonism (as described by Amgen)
Polarity vs dual GIP/GLP-1 agonists
Many late-stage incretin peers (tirzepatide; investigational VK2735) are publicly framed as dual agonists at both GIPR and GLP-1R. MariTide’s public framing is different: GLP-1R agonism + GIPR antagonism [Amgen Phase 2 press 2025-06-23; Amgen MARITIME story].
Amgen states it used genetic expertise to identify GIP receptor inhibition as a key factor in reducing body mass, and that pre-clinical studies showed simultaneous GLP-1 activation + GIP pathway inhibition had a stronger effect on weight loss than targeting either pathway alone — treat as sponsor mechanistic / pre-clinical narrative, not as a clinical ranking vs tirzepatide or retatrutide [Amgen Phase 2 press 2025-06-23].
| Approach | Example | Public GIP polarity | Modality |
|---|---|---|---|
| Mono GLP-1 RA | Semaglutide | None (GLP-1 only) | Peptide |
| Dual GIP/GLP-1 agonist | Tirzepatide; VK2735 (peer) | Agonism | Peptide |
| Triple GIP/GLP-1/glucagon agonist | Retatrutide | Agonism (+ GCGR) | Peptide |
| GLP-1 agonist + GIPR antagonist | MariTide | Antagonism | Ab–peptide conjugate |
| Dual GLP-1/amylin | Zenagamtide | N/A (amylin) | Peptide |
| Dual GCGR/GLP-1 | Survodutide | N/A (glucagon) | Peptide |
Hedges for careful research summaries
- In-vitro potency rankings are assay-specific; this hub does not invent EC50 tables.
- Clinical % weight / HbA1c figures are trial-reported outcomes under named estimands — not reconstitution recipes or personal protocols.
- Cross-trial % weight loss is not a clinical ranking versus retatrutide, CagriSema, zenagamtide, or survodutide.
- Milligram labels in Phase 2 (140 / 280 / 420 mg, etc.) are trial dose labels, not laboratory or personal titration instructions.
Dosing-interval research interest (monthly / less frequent)
Interval language below is sponsor / trial design framing. It is not a personal injection schedule, autoinjector how-to, or RUO reconstitution protocol.
Amgen markets MariTide’s differentiation partly as monthly or less frequent subcutaneous administration relative to weekly incretin peers [Amgen Phase 2 press 2025-06-23; Amgen MARITIME story].
Phase 2 Part 1 explored:
- Fixed doses every 4 weeks (140 / 280 / 420 mg) with and without escalation schemes
- A 420 mg every 8 weeks arm (obesity cohort)
- Escalation arms targeting 420 mg over 4-week or 12-week escalation [Amgen Phase 2 press 2025-06-23; NEJM abstract]
Amgen states Phase 3 MARITIME chronic weight-management studies will evaluate three target doses, each with an initial starting dose of 21 mg, followed by 35 mg and then 70 mg, over an optimized eight-week dose-escalation period — again, trial design, not a use guide [Amgen Phase 2 press 2025-06-23]. MARITIME-1/2 registries describe high / medium / low dose arms over 72 weeks without publishing milligram amounts on the public CT.gov summaries fetched for this draft [NCT06858839; NCT06858878].
Compliance: Do not convert any of the above into a reconstitution, injection, or titration recipe.
MARITIME Phase 3 program map
| Trial | NCT | Population (high-level) | Status (CT.gov fetch 2026-11-05) | Size / notes |
|---|---|---|---|---|
| MARITIME-1 | NCT06858839 | Obesity/overweight without T2D; primary % weight change @ wk 72 | ACTIVE_NOT_RECRUITING; primary completion est. 2027-01-21 | n=3853 actual; high/medium/low dose vs placebo SC |
| MARITIME-2 | NCT06858878 | Obesity/overweight with T2D; primary % weight @ wk 72 | ACTIVE_NOT_RECRUITING; primary completion est. 2027-01-21 | n=1105 actual |
| MARITIME-3-J | NCT06987695 | Japan obesity disease program | ACTIVE_NOT_RECRUITING | n≈279; primary completion est. Apr 2027 |
| MARITIME-OSA-1 | NCT07225686 | OSA on PAP therapy; AHI @ wk 52 | ACTIVE_NOT_RECRUITING | n≈250 |
| MARITIME-OSA-2 | NCT07226765 | OSA not on PAP; AHI @ wk 52 | ACTIVE_NOT_RECRUITING | n≈250 |
| MARITIME-HF | NCT07037459 | HFpEF / mildly reduced EF + obesity | RECRUITING | large outcomes program (n≈5056 listed) |
| MARITIME-CV | NCT07037433 | ASCVD + obesity/overweight; MACE | ACTIVE_NOT_RECRUITING | very large CVOT-style listing (n≈12800 listed) |
| MARITIME-SWITCH | NCT07575399 | Switch from GLP-1 RA; weight @ wk 68 | RECRUITING | n≈300 |
| MARITIME-1 / -2 extensions | NCT07684235 / NCT07684144 | Long-term follow-on for completers | RECRUITING | Extension only |
| MARITIME-T2D-3 | NCT07866066 | T2D open-label vs once-weekly semaglutide | NOT_YET_RECRUITING | HbA1c @ wk 68 theme |
| MARITIME-PEN | NCT07871409 | At-home autoinjector use (no T2D) | NOT_YET_RECRUITING | n≈230; first posted ~Oct 2026 |
Amgen’s June 2025 program story notes additional Phase 3 exploration across cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea [Amgen MARITIME story].
Gap flag: Primary completion dates are estimates and can slip. Active/not-recruiting ≠ topline available. Do not cite unverified “MARITIME topline” blogs.
Phase 2 public results (Amgen / NEJM lineage)
Every figure below is a trial-reported outcome. None of it is a dosing schedule, eligibility recommendation, or product claim for research materials.
Design snapshot
From Amgen’s 23 June 2025 press and ClinicalTrials.gov [Amgen Phase 2 press 2025-06-23; NCT05669599; NEJM DOI 10.1056/NEJMoa2504214]:
| Field | Public value |
|---|---|
| Trial | Phase 2 randomized, double-blind, placebo-controlled, dose-ranging (Part 1) |
| Code / name | AMG 133 → maridebart cafraglutide / MariTide |
| Enrollment | 592 actual |
| Cohort A | Obesity/overweight without T2D (n=465) |
| Cohort B | Obesity/overweight with T2D (n=127) |
| Primary endpoint | % change in body weight baseline → Week 52 |
| Peer-reviewed pointer | Jastreboff AM, et al. N Engl J Med 2025; 393:843–857; DOI 10.1056/NEJMoa2504214 (published 23 June 2025) |
| Status | COMPLETED on CT.gov (primary completion 2024-10-08; completion 2025-12-16) |
Efficacy headlines
Treatment policy estimand (intent-to-treat-style; Amgen footnote 2) — preferred for regulatory-aligned summaries [Amgen Phase 2 press 2025-06-23; NEJM abstract]:
| Cohort | MariTide mean % weight change @ 52 wk (range across arms) | Placebo |
|---|---|---|
| Obesity without T2D | −12.3% to −16.2% | −2.5% |
| Obesity with T2D | −8.4% to −12.3% | −1.7% |
NEJM abstract also reports treatment-policy HbA1c change in the diabetes cohort of −1.2 to −1.6 percentage points vs +0.1 with placebo [NEJM abstract].
Efficacy estimand (Amgen footnote 1 — assumes adherence for the full period) [Amgen Phase 2 press 2025-06-23]:
| Cohort | MariTide (range) | Placebo |
|---|---|---|
| Without T2D | −16.3% to −19.9% (~20% “up to” in headline) | −2.6% |
| With T2D | −12.1% to −17.0% (~17% “up to” in headline) | −1.4% |
| HbA1c (with T2D) | up to −2.2% (press headline) | — |
Amgen notes weight loss had not plateaued by 52 weeks under their framing, and reports improvements in waist circumference, blood pressure, hs-CRP, and select lipids as pre-specified cardiometabolic measures [Amgen Phase 2 press 2025-06-23].
Tolerability (as reported)
Most frequent AEs were gastrointestinal, mostly mild to moderate; GI events were predominantly limited to initial dosing and less frequent with dose escalation. Discontinuation due to GI AEs in dose-escalation arms was up to 7.8%, lower than non-escalation arms per Amgen [Amgen Phase 2 press 2025-06-23]. NEJM abstract: GI AEs common, less frequent with dose escalation and a lower starting dose; no unexpected safety signals [NEJM abstract].
Gap flag: Full NEJM HTML was Cloudflare-blocked during this draft. Prefer reconciling arm-level tables against the journal PDF when unblocked. Do not mix efficacy-estimand “~20%” headlines with treatment-policy −12.3% to −16.2% without labeling the estimand.
Why this is not a simple “research peptide vial”
| Dimension | Typical SaiyanMed peptide SKU | MariTide (public) |
|---|---|---|
| Molecular class | Synthetic peptide API | Antibody–peptide conjugate biologic |
| Receptor story | Often GLP-1 / dual / triple agonist peptides | GLP-1 agonism + GIPR antagonism |
| Catalog fit | Possible with COA + Eric OK | Educational-only indefinitely (this draft) |
| Analytical packet | Peptide HPLC / MS / content | Would need biologic conjugate analytics (Ab + peptide arms) — not a standard peptide COA checklist alone |
| Grey-market risk | Mislabeled powders common | Even higher mismatch risk if something is sold as “MariTide peptide” without conjugate identity |
Explicit: SaiyanMed pages for retatrutide, zenagamtide, CagriSema, and survodutide are class literacy peers — not substitutes, not “same vial family.”
Comparison vs dual agonists (tirzepatide / VK2735) and SaiyanMed hubs
Cross-trial % weight loss is not a clinical ranking. Populations, estimands, durations, and modalities differ.
| Dimension | MariTide | Dual GIP/GLP-1 agonists (e.g. tirzepatide; VK2735 peer) | Retatrutide |
|---|---|---|---|
| Public MoA | GLP-1 agonist + GIPR antagonist | GIPR agonist + GLP-1R agonist | GIP + GLP-1 + glucagon agonist |
| Modality | Ab–peptide conjugate | Peptide | Peptide |
| Interval theme (sponsor) | Monthly / less frequent | Typically weekly (program-dependent) | Weekly research theme |
| Obesity Ph3 example | MARITIME-1/2 (readout pending) | SURMOUNT / VANQUISH (peer programs) | TRIUMPH |
| SaiyanMed SKU | None — edu only | TZP may exist as separate catalog item; VK2735 wait | Soft-link product exists for retatrutide |
Amylin / combo literacy (different problem than GIP polarity):
- Zenagamtide — unimolecular GLP-1/amylin
- CagriSema — two-peptide amylin + GLP-1 combo
- Survodutide — glucagon/GLP-1 dual peptide (BI/Zealand)
Research / analytical identity notes
Why a grey-market label is not clinical identity
“MariTide,” “maridebart cafraglutide,” or “AMG 133” printed on a lyophilized powder does not prove equivalence to Amgen’s clinical-trial drug product. Conjugate biologics can fail by wrong antibody sequence/isotype, incomplete or heterogeneous conjugation, aggregation, host-cell residuals, endotoxin, or simple peptide-only mislabeling. Cake appearance is not an analytical method.
Stock status on SaiyanMed
No MariTide / maridebart cafraglutide catalog SKU is claimed. Educational hub only (site product/post URL check 2026-11-05: /what-is-maritide/ and /what-is-maridebart-cafraglutide/ both 404; no product match). Future biologic conjugate listing would require explicit Eric green-light — not assumed from this article.
Handling themes (no recipes)
This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, autoinjector steps, or study protocols. Clinical milligram labels are trial identifiers only.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “MariTide is just another weekly GLP-1 peptide like semaglutide.” | Public design is an Ab–peptide conjugate with monthly / less frequent SC research framing + GIPR antagonism [Amgen Phase 2 press]. |
| “Same as tirzepatide because both hit GIP and GLP-1.” | Tirzepatide agonizes GIPR; MariTide antagonizes GIPR while agonizing GLP-1R. |
| “Same as retatrutide.” | Retatrutide is a triple agonist peptide (GIP/GLP-1/glucagon) [retatrutide hub]. |
| “~20% Phase 2 means Phase 3 is already known.” | ~20% is an efficacy-estimand Phase 2 headline; MARITIME Ph3 toplines are not public as of this draft. |
| “Treatment-policy −16% and efficacy ~20% are interchangeable.” | Different estimands — label which one you cite [Amgen Phase 2 press]. |
| “SaiyanMed will stock MariTide vials like other peptides.” | Educational-only indefinitely for this conjugate biologic unless explicitly green-lit. |
| “RUO powder = personal monthly weight-loss protocol.” | Explicitly out of scope. |
Glossary
- Maridebart cafraglutide / MariTide / AMG 133: Investigational Amgen Ab–peptide conjugate; GLP-1R agonist + GIPR antagonist.
- Peptide–antibody conjugate / Ab–peptide conjugate: Biologic modality combining antibody and peptide functional arms — not a free peptide API alone.
- GIPR: Glucose-dependent insulinotropic polypeptide receptor.
- GLP-1R: Glucagon-like peptide-1 receptor.
- MARITIME: Amgen Phase 3 program family in obesity and obesity-related conditions.
- Treatment policy estimand: Intent-to-treat-style effect regardless of adherence (Amgen Phase 2 definition).
- Efficacy estimand: Effect under idealized on-treatment assumptions (Amgen Phase 2 definition).
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is MariTide / maridebart cafraglutide?
MariTide is Amgen’s investigational name for maridebart cafraglutide (formerly AMG 133), a long-acting peptide–antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism, studied mainly as a monthly or less frequent subcutaneous investigational product [Amgen Phase 2 press 2025-06-23; NEJM DOI 10.1056/NEJMoa2504214].
Is MariTide a research peptide SaiyanMed can stock like retatrutide?
Not under this hub’s policy. It is a biologic Ab–peptide conjugate, not a simple synthetic peptide vial. SaiyanMed claims no SKU; educational page only.
What did Phase 2 show?
In NCT05669599 (n=592), treatment-policy mean weight change at 52 weeks ranged −12.3% to −16.2% (no T2D) and −8.4% to −12.3% (with T2D) vs placebo −2.5% / −1.7%; efficacy-estimand ranges reached about −16.3% to −19.9% and −12.1% to −17.0% respectively [Amgen Phase 2 press; NEJM abstract].
Are Phase 3 MARITIME results out?
Not claimed here. MARITIME-1/2 are ACTIVE_NOT_RECRUITING with estimated primary completion 21 Jan 2027 [NCT06858839; NCT06858878].
How does MariTide differ from tirzepatide?
Public polarity at GIPR differs (antagonist vs agonist), and modality differs (Ab–peptide conjugate vs peptide dual agonist).
How does it differ from retatrutide / zenagamtide / CagriSema / survodutide?
See class tables above and SaiyanMed hubs: retatrutide, zenagamtide, CagriSema, survodutide.
Is MariTide FDA-approved?
No. Amgen states it is investigational; scientific information in the Phase 2 press is preliminary and not approved by FDA [Amgen Phase 2 press 2025-06-23].
Can I use these trial milligrams or % weight figures as a personal protocol?
No. This page provides no dosing, reconstitution, titration, or injection guidance.
Key takeaways
- MariTide = maridebart cafraglutide (AMG 133) — Amgen Ab–peptide conjugate; GLP-1 agonism + GIPR antagonism; monthly / less frequent SC research theme.
- Not a simple SaiyanMed-style peptide vial; no product SKU; educational indefinitely.
- Phase 2 (NEJM / Amgen 2025-06-23): treatment-policy −12.3% to −16.2% (no T2D) and −8.4% to −12.3% (T2D) at 52 weeks; efficacy-estimand headlines ~20% / ~17%.
- Phase 3 MARITIME-1 (n=3853) and MARITIME-2 (n=1105) fully enrolled / active not recruiting; primary completion est. Jan 2027 — no Ph3 topline in this draft.
- Class literacy: cross-link retatrutide, zenagamtide, CagriSema, survodutide.
Related reading & research inquiry
- What Is Retatrutide?
- What Is Zenagamtide (Amycretin)?
- What Is CagriSema?
- What Is Survodutide?
- Optional amylin mono literacy: What Is Petrelintide? · What Is Eloralintide?
CTA (SKU-gated): This page does not invent a MariTide inventory listing. Antibody–peptide conjugates are outside SaiyanMed’s default peptide catalog path unless Eric explicitly green-lights a biologic SKU after identity/COA review.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and company IR information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. Maridebart cafraglutide / MariTide remains an investigational candidate unless and until a regulator issues an approved label — and even then, approved product labels are not RUO protocols. This article is not a substitute for any approved medicine’s label and is not a use guide for research powders or biologic conjugates.
Sources & further reading
- Amgen — Phase 2 MariTide ADA / NEJM press (2025-06-23) — amgen.com newsroom
- Amgen IR mirror — investors.amgen.com
- NEJM Phase 2 — DOI 10.1056/NEJMoa2504214
- Amgen — Inside MARITIME Phase 3 story — amgen.com stories
- ClinicalTrials.gov NCT05669599 — Phase 2
- ClinicalTrials.gov NCT06858839 / NCT06858878 — MARITIME-1 · MARITIME-2
- Additional MARITIME NCTs — OSA / HF / CV / SWITCH / PEN / extensions (linked in program map)
- SaiyanMed class hubs — retatrutide · zenagamtide · CagriSema · survodutide